HUP0001192A2 - Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására - Google Patents

Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására

Info

Publication number
HUP0001192A2
HUP0001192A2 HU0001192A HUP0001192A HUP0001192A2 HU P0001192 A2 HUP0001192 A2 HU P0001192A2 HU 0001192 A HU0001192 A HU 0001192A HU P0001192 A HUP0001192 A HU P0001192A HU P0001192 A2 HUP0001192 A2 HU P0001192A2
Authority
HU
Hungary
Prior art keywords
derivatives
topiramate
preparation
pharmaceutical compositions
treating obesity
Prior art date
Application number
HU0001192A
Other languages
English (en)
Inventor
Richard P. Shank
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21807338&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0001192(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of HUP0001192A2 publication Critical patent/HUP0001192A2/hu
Publication of HUP0001192A3 publication Critical patent/HUP0001192A3/hu
Publication of HU226775B1 publication Critical patent/HU226775B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

A találmány (I) általános képletű szulfamátszármazékok - a képletben X jelentése CH2 vagy oxigénatom; R1 jelentése hidrogénatom vagy alkilcsoport, R2, R3, R4 és R5 jelentése egymástól függetlenül hidrogénatom vagyrövid szénláncú alkoxicsoport, és ha X jelentése oxigénatom, R2 és R3és/vagy R4 és R5 együtt metilén-dioxi-csoportot is alkothat -alkalmazására vonatkozik elhízás kezelésére alkalmas gyógyszerelőállítására. Ó
HU0001192A 1996-06-28 1997-06-23 The use of topiramate and its derivatives for preparation of pharmaceutical compositions useful for treating obesity or for weight loss HU226775B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2200496P 1996-06-28 1996-06-28
PCT/US1997/010953 WO1998000130A2 (en) 1996-06-28 1997-06-23 Anticonvulsant sulfamate derivatives useful in treating obesity

Publications (3)

Publication Number Publication Date
HUP0001192A2 true HUP0001192A2 (hu) 2000-11-28
HUP0001192A3 HUP0001192A3 (en) 2002-09-30
HU226775B1 HU226775B1 (en) 2009-09-28

Family

ID=21807338

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001192A HU226775B1 (en) 1996-06-28 1997-06-23 The use of topiramate and its derivatives for preparation of pharmaceutical compositions useful for treating obesity or for weight loss

Country Status (24)

Country Link
US (1) US6071537A (hu)
EP (1) EP0915697B1 (hu)
JP (1) JP2000514425A (hu)
CN (1) CN1106193C (hu)
AP (1) AP1285A (hu)
AT (1) ATE224189T1 (hu)
AU (1) AU732923B2 (hu)
BR (1) BR9710994A (hu)
CA (1) CA2258893C (hu)
CZ (1) CZ293876B6 (hu)
DE (1) DE69715631T2 (hu)
DK (1) DK0915697T3 (hu)
ES (1) ES2184127T3 (hu)
HK (1) HK1018743A1 (hu)
HU (1) HU226775B1 (hu)
IL (1) IL127715A (hu)
NO (1) NO317754B1 (hu)
NZ (1) NZ333586A (hu)
PT (1) PT915697E (hu)
RU (1) RU2214241C2 (hu)
SK (1) SK284305B6 (hu)
UA (1) UA53655C2 (hu)
WO (1) WO1998000130A2 (hu)
ZA (1) ZA975772B (hu)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
DK1158973T3 (da) * 1999-02-24 2005-05-30 Univ Cincinnati Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser
AU4050100A (en) * 1999-04-08 2000-11-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
JP4825353B2 (ja) * 1999-04-08 2011-11-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 血圧を下げることに有用な抗痙攣薬誘導体
MXPA01010218A (es) * 1999-04-08 2002-03-27 Johnson & Johnson Derivados anticonvulsivos utiles para disminuir lipidos.
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
JP4709392B2 (ja) * 1999-04-08 2011-06-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 血液グルコースレベルを下げることに有用な抗痙攣薬誘導体
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
WO2002003984A2 (en) 2000-07-07 2002-01-17 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
NZ537490A (en) * 2000-10-30 2006-11-30 Ortho Mcneil Pharm Inc Treatment of diabetes and syndrome X using a sulfamate derivate such as topiramate and metformin
AU2002227052A1 (en) 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
CN1320886C (zh) * 2002-05-17 2007-06-13 杜克大学 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2489984A1 (en) * 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
WO2004050081A1 (en) * 2002-12-02 2004-06-17 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
DK2316456T3 (en) * 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
EP1734955A2 (en) 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0514278A (pt) * 2004-08-24 2008-06-10 Janssen Pharmaceutica Nv derivados de sulfamida de heteroarila benzo-fundida úteis como agentes anti-convulsivante
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
KR101654176B1 (ko) 2006-11-09 2016-09-09 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
ES2802048T3 (es) 2012-06-06 2021-01-15 Nalpropion Pharmaceuticals Llc Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4586916A (en) * 1985-01-30 1986-05-06 Consolidated Papers, Inc. Corrugated carton separator
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates

Also Published As

Publication number Publication date
AU3957897A (en) 1998-01-21
CA2258893A1 (en) 1998-01-08
ES2184127T3 (es) 2003-04-01
HU226775B1 (en) 2009-09-28
DE69715631T2 (de) 2003-05-08
DE69715631D1 (de) 2002-10-24
PT915697E (pt) 2003-02-28
CZ427898A3 (cs) 1999-08-11
NO317754B1 (no) 2004-12-13
CN1106193C (zh) 2003-04-23
ZA975772B (en) 1998-12-28
IL127715A0 (en) 1999-10-28
AU732923B2 (en) 2001-05-03
JP2000514425A (ja) 2000-10-31
NZ333586A (en) 2000-05-26
IL127715A (en) 2004-07-25
AP1285A (en) 2004-06-24
AP9801429A0 (en) 1998-12-31
SK180598A3 (en) 2000-07-11
DK0915697T3 (da) 2003-01-27
WO1998000130A3 (en) 1998-02-12
BR9710994A (pt) 2000-10-24
CA2258893C (en) 2005-06-14
NO986052D0 (no) 1998-12-22
HUP0001192A3 (en) 2002-09-30
US6071537A (en) 2000-06-06
WO1998000130A2 (en) 1998-01-08
CN1224352A (zh) 1999-07-28
EP0915697B1 (en) 2002-09-18
RU2214241C2 (ru) 2003-10-20
SK284305B6 (sk) 2005-01-03
NO986052L (no) 1999-02-23
HK1018743A1 (en) 2000-01-07
EP0915697A2 (en) 1999-05-19
UA53655C2 (uk) 2003-02-17
ATE224189T1 (de) 2002-10-15
CZ293876B6 (cs) 2004-08-18

Similar Documents

Publication Publication Date Title
HUP0001192A2 (hu) Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására
HUP0402225A2 (hu) Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0003381A2 (hu) Topiramát és származékai alkalmazása mániás depressziós bipoláris rendellenesség kezelésére alkalmas gyógyszerek előállítására
HUP0001993A2 (hu) Fungicid hatású (trifluor-metil-alkil)-amino-triazol 0[1,5-a]pirimidin-származékok, előállításuk és alkalmazásuk
HUP0000449A2 (hu) N-szubsztituált dioxo-tiazolidil-benzamid-származékok és eljárás a vegyületek előállítására
DK0794949T3 (da) Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler
HUP0303037A2 (hu) Alzheimer-kór kezelésére alkalmas vegyületek és ezeket tartalmazó gyógyszerkészítmények
MY119150A (en) Azetidine derivatives, their preparation and medicaments containing them
IL123293A0 (en) Piperidine derivatives their preparation and use
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
HUP0300922A2 (hu) Új vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0400561A2 (hu) 3-Aroilindol-származékok és a vegyületek CB2 receptor agonistaként való alkalmazása, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402235A2 (hu) 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények
FR2712591B1 (fr) Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
HUP0401235A2 (hu) 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0001164A2 (hu) PF1022-ciklodepszipeptid-származékok
IE892795L (en) Ó,Ó-Disubstituted N-cycloalkylalkylbenzylamines, process for¹their preparation, their use as a medicament and their¹synthesis intermediates
MY113427A (en) Anti-neurodegeneratively active 10-aminoaliphatyl- dibenz [b,f] oxepines
HUP0102025A2 (hu) Diaril-1,3,4-oxadiazolon-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9904294A2 (hu) Topiramát származékok alkalmazása neuropátiás fájdalom kezelésére alkalmas gyógyszer előállítására
FI884088A (fi) Foerfarande foer framstaellning av 17-substituerade androsta-1,4-dien-3-onderivat.
ES2152563T3 (es) Procedimiento para preparar derivados de dihidroxipirimidina.
TW334340B (en) Preparation for pyrazolyl derivatives
NO870423L (no) 5-substituerte oktahydroindolizin-analgetiske forbindelser og 7-keto mellomprodukter.